ANVS · Annovis Bio, Inc.
$1.79
-0.03 (-1.65%)
At close · Aug 26
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Management has concluded that substantial doubt exists about the Company's ability to continue as a going concern. Management's plans to mitigate this risk include raising additional capital through equity financings, debt, or other potential alternatives. Management's plans may also include the deferral of certain operating expenses unless and until additional capital is received. However, there can be no assurance that the Company will be successful in raising additional capital or that such capital, if available, will be on terms that are acceptable to the Company, or that the Company will be successful in deferring certain operating expenses. As such, Management has concluded that such plans do not alleviate the aforementioned substantial doubt.”View the 10-Q filed Aug 14, 2026
Market Cap
$77.33M
Shares
42.61M
Annovis Bio, Inc. Earnings Call Transcripts
Quarterly earnings calls for Annovis Bio, Inc. (ANVS), with available speaker-labelled transcripts, captured audio replays, call highlights, 8-K earnings releases and periodic filings. Investor days and conferences appear here too.
Earnings call
FY25 · Q2
2025-08-12
Annovis Bio, Inc. (ANVS) Q2 2025 Earnings Call
Diluted EPS
$-0.32
Rev · 6q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-03-21
Annovis Bio, Inc. (ANVS) Q4 2024 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Showing 1–2 of 2 earnings calls
Key facts
CIK
1477845
CUSIP
03615A108
13F (30d)
58 filings
57 filers
Visit website
Investor relations